What Hyasynth Bio does

Hyasynth Bio (legally Hyasynth Biologicals Inc.) is a Montreal-based biotechnology company founded in 2014 that produces pharmaceutical-grade cannabinoids via yeast fermentation rather than plant cultivation. The company has engineered proprietary yeast strains that autonomously synthesize cannabinoids as part of their natural growth cycle, requiring only standard inputs (water, sugar, air) without specialized precursors. After a controlled 3-5 day fermentation cycle monitored for temperature, acidity, growth rate, inputs, and gas outputs, the cannabinoids are separated and purified using food and pharmaceutical-grade solvents in a sterile, fully automated process. The platform is designed to scale to hundreds of thousands of litres for mass-market health product supply.

The company's product portfolio includes isolated, high-purity cannabinoids for research and product formulation, plus finished end products in pill, oil, and topical cream formats. It also offers custom cannabinoid combinations tailored for specific therapeutic applications and is pursuing rare cannabinoid discovery for future pharmaceutical products. Hyasynth operates as a Licensed Dealer under Health Canada's Narcotic Control Regulations, which permits it to produce and distribute controlled cannabinoid products only to entities authorized to possess them.

The company employs 11-50 staff and runs a B2B direct sales model in which prospective customers must register through a Typeform sales portal and disclose their regulatory authorization status. Revenue, when generated, derives from one-time sales of bulk isolated cannabinoids and custom formulations to three customer segments: cannabinoid product manufacturers (primary), research institutions, and pharmaceutical R&D clients. The company has raised approximately CAD $13.16M+ across multiple funding rounds since inception, with Organigram — a major Canadian licensed cannabis producer — serving as lead investor in the three most recent disclosed rounds (May 2018, October 2020, December 2021). Earlier backers include SOSV, Rebel Bio, Anges Québec, and the Québec government's Ministère de l'Économie et de l'Innovation.

Name

Hyasynth Bio

Legal name

Hyasynth Biologicals Inc.

Website

https://hyasynthbio.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Hyasynth Bio is a Montreal-based biotechnology company founded in 2014 that produces pharmaceutical-grade cannabinoids through engineered yeast fermentation, supplying isolated compounds and custom formulations in pill, oil, and topical formats to authorized product manufacturers, research institutions, and pharmaceutical R&D clients under its Health Canada Licensed Dealer permit.

Ownership category

akta.pro rank

Product category

Biosynthetic Cannabinoid Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI)

Keywords

• Cannabinoid biosynthesis
• Yeast fermentation
• Pharmaceutical ingredients
• Natural health products
• Biotech manufacturing

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Bulk Cannabinoid Sales: Sale of isolated, high-quality, pure cannabinoids produced via yeast fermentation. Products can be sold as isolated compounds for research or combined into formulations.
2. Custom Cannabinoid Formulations: Production of combinations of multiple cannabinoids formatted into pills, oils, topical creams, or other delivery formats for product manufacturers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Hyasynth Bio produces pure, pharmaceutical-grade cannabinoids through yeast-based biosynthesis. Specially engineered yeast strains autonomously produce cannabinoids during a 3-5 day fermentation process using only standard growth inputs (water, sugar, air). The cannabinoids are then separated, purified with food/pharmaceutical-grade solvents, and supplied as isolated compounds or formulated into pills, oils, or topical creams for authorized B2B buyers.

Product overview

Hyasynth Bio is a biotechnology company that produces natural health products through yeast-based biosynthesis of cannabinoids. Their core product is isolated, pure cannabinoids produced by engineered yeast strains, which are then formulated into final consumer products including pills, oils, and topical creams. The company operates under a Licensed Dealer permit from Health Canada and focuses on producing pharmaceutical-grade cannabinoid ingredients and custom formulations for the healthcare industry. The production process spans from engineered yeast fermentation (3-5 days) through separation, purification, and formulation into final product formats.

Differentiator

Problem solved

Functional benefit

Products and services

• Isolated Cannabinoids Pure, high-quality cannabinoid compounds produced through engineered yeast fermentation, isolated from the fermentation mixture and purified with food and pharmaceutical-grade solvents. Sold in bulk to authorized buyers including research institutions and product manufacturers.
• Cannabinoid Pills Cannabinoid formulations combined into pill format for oral consumption, supplied as finished dosage units to authorized B2B customers.
• Cannabinoid Oils Cannabinoid formulations in oil format suitable for oral consumption or topical application, supplied to authorized B2B customers.
• Cannabinoid Topical Creams Cannabinoid formulations in topical cream format for external application, supplied to authorized B2B customers.
• Custom Cannabinoid Formulations Custom combinations of multiple cannabinoids formatted into pills, oils, topical creams, or other delivery formats, tailored to specific buyer applications including pharmaceutical R&D and disease-targeted products.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Trait Biosciences: Cannabis biotech focused on water-soluble cannabinoid formulations and derivative technologies. Partial overlap with Hyasynth's downstream formulation capabilities (oils, topicals) but uses different production methodology (plant-derived, not yeast-fermented).
• InMed Pharmaceuticals: Pharmaceutical company developing cannabinoid-based prescription therapeutics, including rare cannabinoid formulations for specific disease indications. Overlaps with Hyasynth's stated interest in pharma R&D and rare cannabinoid discovery.

Others

• Organigram: Lead investor in Hyasynth and a major Canadian cannabis producer. Functions as both strategic backer and likely anchor offtake customer, with potential to internalize similar biosynthesis capabilities in-house over time.

Broad incumbents

• Ginkgo Bioworks: Large synthetic biology platform that has partnered with Cronos Group to develop cannabinoid-producing yeast strains. Broader scope across multiple industries, but directly competing for the same cannabinoid biosynthesis opportunity with substantially greater capital and infrastructure.
• Amyris: Industrial synthetic biology company using yeast fermentation to produce specialty ingredients (originally terpenes, now broader ingredient portfolio). Demonstrates the production model Hyasynth employs, though Amyris operates at much larger scale and across multiple end-markets.
• Cronos Group: Major Canadian licensed cannabis producer that has invested in fermentation-based cannabinoid production through its partnership with Ginkgo Bioworks. Represents both a potential customer/partner and competitor with vertically integrated capabilities and significant balance sheet.

Direct peers

• Cellibre: Cell-based manufacturing company using engineered yeast and microorganisms to produce cannabinoids and other high-value ingredients. Direct competitor with similar B2B ingredient-supply model targeting cannabinoid formulators.
• CB Therapeutics: San Diego-based biotech using yeast and fungal fermentation to produce cannabinoids and other fungal-derived compounds. Direct overlap in core technology and product offering (isolated cannabinoids via biosynthesis).
• Demetrix (Antheia): Closest comparable: yeast-based biosynthesis platform producing cannabinoids and opioid APIs. Same technology category (engineered yeast fermentation for plant-derived compounds) and same end customer base (pharma, consumer health). Highly relevant as the most-funded direct competitor in this niche.
• Biomedican: Biotech developing proprietary yeast strains for biosynthesis of cannabinoids and other pharmaceutical compounds. Direct competitor with overlapping technology platform and target market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/HyasynthBio
• Facebookfacebook.com/hyasynthbio
• LinkedInlinkedin.com/company/hyasynth-biologicals
• Instagraminstagram.com/hyasynthbio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds10 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyasynth Bio